Literature DB >> 20046096

The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways.

Mustapha Kandouz1, Khadidja Haidara, Jing Zhao, Marie-Laure Brisson, Gerald Batist.   

Abstract

EphB2 is a tyrosine kinase receptor that has been shown to be a tumor suppressor gene in various cancers. However the mechanisms of this function are unknown. We report that EphB2 induces a form of cell death that does not involve the formation of apoptotic bodies or nuclear fragmentation and is instead accompanied by extensive vacuolization. Transmission electron microscopy demonstrates cytoplasmic vacuoles in EphB2-overexpressing cells that resembled autophagosomes. Using an EYFP-LC3 fusion protein and immunoblotting, we detected LC3 aggregation and conversion from form I to form II, both hallmarks of autophagy, in EphB2-transfected cells. Silencing of the autophagy regulating genes ATG5 or ATG7 using shRNAs, strongly prevented EphB2-induced cell death, further confirming its autophagic nature. EphB2 expression results in mitochondrial depolarization and translocation of cytochrome c from the mitochondria to the cytosol. Mapping of signaling pathways revealed novel information about the mechanisms of action of EphB2. We demonstrated that the MAPK pathway is important in the pro-death action of EphB2, through ERK1/2 phosphorylation and inhibition of this pathway using PD98059 counters EphB2-driven cell death. In addition, we found that inhibition of class III PI3K pathway, using the autophagy inhibitor 3MA, but not class I PI3K inhibition using LY294002, also effectively blocks EphB2- induced cell death. Finally, EphB2 expression inactivates Akt, which is a known inhibitor of autophagy. In conclusion, the EphB2 receptor induces an autophagic cell death that is mediated through the ERK1/2 and PI3K/Akt pathways.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20046096     DOI: 10.4161/cc.9.2.10505

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  20 in total

1.  Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells.

Authors:  Nai-Ying Yang; Carlos Fernandez; Melanie Richter; Zhan Xiao; Fatima Valencia; David A Tice; Elena B Pasquale
Journal:  Cell Signal       Date:  2010-09-15       Impact factor: 4.315

2.  Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.

Authors:  M Danielle Bareford; Hossein A Hamed; Jeremy Allegood; Nichola Cruickshanks; Andrew Poklepovic; Margaret A Park; Besim Ogretmen; Sarah Spiegel; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2012-06-07       Impact factor: 4.742

Review 3.  Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Authors:  Linda S Steelman; William H Chappell; Stephen L Abrams; Ruth C Kempf; Jacquelyn Long; Piotr Laidler; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Franca Stivala; Maria C Mazzarino; Marco Donia; Paolo Fagone; Graziella Malaponte; Ferdinando Nicoletti; Massimo Libra; Michele Milella; Agostino Tafuri; Antonio Bonati; Jörg Bäsecke; Lucio Cocco; Camilla Evangelisti; Alberto M Martelli; Giuseppe Montalto; Melchiorre Cervello; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-03       Impact factor: 5.682

4.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Authors:  William H Chappell; Stephen L Abrams; Richard A Franklin; Michelle M LaHair; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Michele Milella; Agostino Tafuri; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

5.  Loss of tyrosine kinase receptor Ephb2 impairs proliferation and stem cell activity of spermatogonia in culture†.

Authors:  Thierry N'Tumba-Byn; Makiko Yamada; Marco Seandel
Journal:  Biol Reprod       Date:  2020-04-15       Impact factor: 4.285

6.  RNF186 regulates EFNB1 (ephrin B1)-EPHB2-induced autophagy in the colonic epithelial cells for the maintenance of intestinal homeostasis.

Authors:  Huazhi Zhang; Zhihui Cui; Du Cheng; Yanyun Du; Xiaoli Guo; Ru Gao; Jianwen Chen; Wanwei Sun; Ruirui He; Xiaojian Ma; Qianwen Peng; Bradley N Martin; Wei Yan; Yueguang Rong; Chenhui Wang
Journal:  Autophagy       Date:  2020-12-17       Impact factor: 16.016

7.  Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Authors:  Jackson R Taylor; Brian D Lehmann; William H Chappell; Stephen L Abrams; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2011-08

8.  High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFPAC-1 cells through the EphrinB1-EphB2 pathway.

Authors:  Yong-Qiang Hua; Zhen Chen; Zhi-Qiang Meng; Hao Chen; Jian-Gang Shen; Kun Wang; Wang Peng; Ye-Hua Shen; Lu-Ming Liu
Journal:  Oncol Lett       Date:  2014-05-12       Impact factor: 2.967

Review 9.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Ferdinando Nicoletti; Paolo Fagone; Grazia Malaponte; Maria C Mazzarino; Saverio Candido; Massimo Libra; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Lucio Cocco; Camilla Evangelisti; Francesca Chiarini; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-09

Review 10.  Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

Authors:  James A McCubrey; Linda S Steelman; William H Chappell; Stephen L Abrams; Richard A Franklin; Giuseppe Montalto; Melchiorre Cervello; Massimo Libra; Saverio Candido; Grazia Malaponte; Maria C Mazzarino; Paolo Fagone; Ferdinando Nicoletti; Jörg Bäsecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Michele Milella; Agostino Tafuri; Francesca Chiarini; Camilla Evangelisti; Lucio Cocco; Alberto M Martelli
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.